Multiple Myeloma Refractory
47
18
20
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
4.3%
2 terminated out of 47 trials
71.4%
-15.1% vs benchmark
4%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (47)
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
CAR-T in Relapsed/Refractory Multiple Myeloma
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Universal CAR-T Cell Therapy for MM
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies